← All compounds
peptide24 listings
Melanotan I
Afamelanotide
More selective MC1R agonist. Some FDA approval for specific applications.
Pigmentation researchPhotoprotection research
/ research index
The research base
Research Maturity
★★★★☆
4/5 — Volume of studies
Evidence Strength
★★★★☆
4/5 — Quality of evidence
FDA approved for erythropoietic protoporphyria research.
/ mechanism of action
How it works
Selective MC1R agonist.
/ research dosing
Common research protocols
Range
0.16 mg/kg per dose (afamelanotide = MT-I)
Frequency
Implant every 60 days (clinical) or research dosing varies
Route
Subcutaneous implant (FDA-approved form)
Cycle
Clinical: implant every 2 months
Research notes
FDA-approved as Scenesse (afamelanotide) for erythropoietic protoporphyria. Slower onset, longer duration than MT-II. Less side effect profile than MT-II.
References
FDA Scenesse labelPMID: 26154787 →
FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.
/ standalone use
As a solo compound
FDA-approved standalone use.
/ side effects
What to know
Generally well-tolerated.
/ timeline
Realistic expectations
2-4 weeks
/ recommendation
Where to buy Melanotan I
🏆Our pick for Melanotan I
Valor Peptides
10mg · USA · Card / Crypto
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Comprehensive
- ✓Highest verification tier in stock
- ✓4.8★ community rating
Also solid
/ all listings
Full index, price per mg
Supplier
Trust Score
Size
Price
$/mg
Stock
Buy
FOR RESEARCH USE ONLY. Melanotan I is intended for laboratory research and not for human consumption.